Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Liposomes
Reexamination Certificate
2007-10-23
2007-10-23
McGarry, Sean (Department: 1635)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Liposomes
C435S091100, C536S023100, C536S024300, C536S024500, C514S04400A
Reexamination Certificate
active
09381747
ABSTRACT:
The present invention provides novel compositions and methods for use in the treatment of Bcl-2-associated diseases like cancer, specifically, in the treatment of follicular lymphoma (FL). The compositions contain antisense oligonucleotides that hybridize to Bcl-2 nucleic acids, the gene products of which are known to interact with the tumorigenic protein Bcl-2. Used alone, or in conjunction with other antisense oligonucleotides, these compositions inhibit the proliferation of FL cancer cells.
REFERENCES:
patent: 4229360 (1980-10-01), Schneider et al.
patent: 4394448 (1983-07-01), Szoka, Jr. et al.
patent: 4469863 (1984-09-01), Ts'o et al.
patent: 4480041 (1984-10-01), Myles et al.
patent: 4721612 (1988-01-01), Janoff et al.
patent: 4835263 (1989-05-01), Nguyen et al.
patent: 4837028 (1989-06-01), Allen
patent: 4904582 (1990-02-01), Tullis
patent: 4920016 (1990-04-01), Allen et al.
patent: 4924624 (1990-05-01), Suhadolnik et al.
patent: 4950432 (1990-08-01), Mehta et al.
patent: 5015568 (1991-05-01), Tsujimoto et al.
patent: 5030442 (1991-07-01), Uster et al.
patent: 5049388 (1991-09-01), Knight et al.
patent: 5087617 (1992-02-01), Smith
patent: 5094785 (1992-03-01), Law et al.
patent: 5098890 (1992-03-01), Gewirtz et al.
patent: 5100662 (1992-03-01), Bolcsak et al.
patent: 5112962 (1992-05-01), Letsinger et al.
patent: 5135917 (1992-08-01), Burch
patent: 5178875 (1993-01-01), Lenk et al.
patent: 5188897 (1993-02-01), Suhadolnik et al.
patent: 5202429 (1993-04-01), Tsujimoto et al.
patent: 5227170 (1993-07-01), Sullivan
patent: 5248671 (1993-09-01), Smith
patent: 5264618 (1993-11-01), Felgner et al.
patent: 5271941 (1993-12-01), Cho-Chung
patent: 5279833 (1994-01-01), Rose
patent: 5279957 (1994-01-01), Gross
patent: 5320962 (1994-06-01), Stiles et al.
patent: 5324654 (1994-06-01), Bredesen
patent: 5376646 (1994-12-01), Pittrof et al.
patent: 5378825 (1995-01-01), Cook et al.
patent: 5417978 (1995-05-01), Tari et al.
patent: 5459251 (1995-10-01), Tsujimoto et al.
patent: 5527538 (1996-06-01), Baldeschwieler
patent: 5539085 (1996-07-01), Bischoff et al.
patent: 5539094 (1996-07-01), Reed et al.
patent: 5560923 (1996-10-01), Rahman et al.
patent: 5565337 (1996-10-01), Diamond et al.
patent: 5583034 (1996-12-01), Green et al.
patent: 5622852 (1997-04-01), Korsmeyer
patent: 5641662 (1997-06-01), Debs et al.
patent: 5661018 (1997-08-01), Ashley et al.
patent: 5665710 (1997-09-01), Rahman et al.
patent: 5696248 (1997-12-01), Peyman et al.
patent: 5705385 (1998-01-01), Bally et al.
patent: 5734033 (1998-03-01), Reed
patent: 5750669 (1998-05-01), Rosch et al.
patent: 5756122 (1998-05-01), Thierry et al.
patent: 5817811 (1998-10-01), Breipohl et al.
patent: 5831048 (1998-11-01), Schwighoffer et al.
patent: 5831066 (1998-11-01), Reed
patent: 5837838 (1998-11-01), Reed et al.
patent: 5855911 (1999-01-01), Lopez-Berestein et al.
patent: 5874224 (1999-02-01), Bandman et al.
patent: 5874553 (1999-02-01), Peyman et al.
patent: 5891714 (1999-04-01), Ashley et al.
patent: 5908635 (1999-06-01), Thierry
patent: 5976567 (1999-11-01), Wheeler et al.
patent: 5981501 (1999-11-01), Wheeler et al.
patent: 5989912 (1999-11-01), Arrow et al.
patent: 6015886 (2000-01-01), Dale et al.
patent: 6030954 (2000-02-01), Wu et al.
patent: 6034235 (2000-03-01), Sugiyama et al.
patent: 6040181 (2000-03-01), Reed
patent: 6042846 (2000-03-01), Lopez-Berestein et al.
patent: 6096720 (2000-08-01), Love et al.
patent: 6110490 (2000-08-01), Thierry
patent: 6120794 (2000-09-01), Liu et al.
patent: 6120798 (2000-09-01), Allen et al.
patent: 6126965 (2000-10-01), Kasid et al.
patent: 6136965 (2000-10-01), Bruice et al.
patent: 6211162 (2001-04-01), Dale et al.
patent: 6211349 (2001-04-01), Dale et al.
patent: 6277832 (2001-08-01), Sugiyama et al.
patent: 6277981 (2001-08-01), Tu et al.
patent: 6291668 (2001-09-01), Ziegler et al.
patent: 6326487 (2001-12-01), Peyman et al.
patent: 2171589 (1996-01-01), None
patent: 4110085 (1991-03-01), None
patent: 0 252 685 (1988-01-01), None
patent: WO88/04924 (1988-07-01), None
patent: WO89/06977 (1989-08-01), None
patent: WO90/09180 (1990-08-01), None
patent: WO90/10488 (1990-09-01), None
patent: WO91/16901 (1991-11-01), None
patent: WO92/21330 (1992-12-01), None
patent: WO93/07883 (1993-04-01), None
patent: WO93/11245 (1993-06-01), None
patent: 93/202200 (1993-10-01), None
patent: WO93/20200 (1993-10-01), None
patent: WO93/20200 (1993-10-01), None
patent: WO93/24653 (1993-12-01), None
patent: WO94/04545 (1994-03-01), None
patent: WO94/05259 (1994-03-01), None
patent: WO95/03788 (1995-02-01), None
patent: 95/08350 (1995-03-01), None
patent: WO95/08350 (1995-03-01), None
patent: WO95/08350 (1995-03-01), None
patent: WO95/28497 (1995-10-01), None
patent: WO96/27663 (1996-09-01), None
patent: WO96/40062 (1996-12-01), None
patent: WO97/07784 (1997-03-01), None
patent: WO98/14172 (1998-04-01), None
patent: WO98/56905 (1998-12-01), None
patent: WO 00/40595 (2000-07-01), None
patent: WO 02/17852 (2002-03-01), None
Agrawal, “Antisense oligonucleotides: towards clinical trials” TIBTech, vol. 14, p. 376-387, Oct. 1996.
Branch,“A good antisense molecule is hard to find”, TIBS 23, p. 45-50, Feb. 1998.
Crooke, “Antisense research and application” Springer, New York, p. 1-50, Jul. 1998.
Gura, Science, vol. 278, p. 1041-1042, Nov. 1997.
Golden, Time, vol. 151, (19), p. 44.
Crooke, ST, Basic Principles of Antisense Therapeutics. Antisense Research and Application (1998), Chapter 1, Springer-Verlag, New York.
Crooke, St, Potential roles of antisense technology in cancer chemotherapy. Oncogene (2000), vol. 19, 6651-6659. Macmillan Publishers Ltd.
Korsmeyer et al. Bcl-2?Bax: a rheostat that regulates an anti-oxidant pathway and cell death. Cancer Biology, 1993, vol. 4: 327-332. Academic Press Ltd.
M.T. Almazan et al., “Methylphosphonate-containing oligonucleotides efficiently and specifically inhibit Bcl-2 and erbB-2 expression in vitro,”Proc. Amer. Assoc. Cancer Res.,37:353, Abstract No. 2407, Mar. 1996.
M. Tormo et al., “Antitumor activity of liposomal-bcl-2-antisense ologonucleotides in follicular lymphoma,”Proc. Amer. Assoc. Cancer Res.,37:173, Abstract No. 1190, Mar. 1996.
Fred D. Ledley, “Non-viral gene therapy,”Current Opinion in Biotechnology, 5:626-636, 1994.
Yongyut Rojanasakul, “Antisense oligonucleotide therapeutics: drug delivery and targeting,”Adv. Drug Delivery Reviews,18:115-131, 1996.
Abubakr et al., Effectiveness of Bcl-2 antisense oliogodeoxynucleotides (AS-ODN) against human follicular small-cleaved cell lymphoma (FSCCL)-SCID mice xenograft model,Blood,84 (10 Suppl. 1) 374A, 1994.
Agris et al., “Inhibition of vesicular stomatitis virus protein synthesis and infection by sequence-specific oligodeoyribonucleoside methylposphonates,”Biochemistry,25:6268-6275, 1986.
Akhtar et al., “Interactions of antisense DNA oligonucleotide analogs with phospholipid membranes (liposomes),”Nucleic Acids Research,19(20): 5551-5559, 1991.
Akhtar et al., “Release of antisense oligdeoynucleotide analogues from liposomes: implications for cellular transport and drug delivery,” 128th Meeting of British Pharmaceutical Conference 1991, United Kingdom, Sep. 10-13, 1991,J. Pharm. Pharmacol.,43 (Suppl.):Abstrast 24P, 1991.
Aktar et al., “Lipsome Delivery of Antisense Methylphosphonate and Phosphorothioate Oligonucleotides: A Study with MLV, FATMLV, and LUV Liposomes,”Proceed. Intern. Symp. Control. Rel. Bioact. Mater.,19:345-346, 1992.
Allsopp et al., “The Proto-Oncogene bcl-2 Can Selectively Rescue Neurotrophic Factor-Dependent Neurons from Apoptosis,”Cell,73: 295, 1993.
Arad et al., “Use of reconstituted sendai virus envelopes for fusion-mediated microinjection of double-stranded RNA: Inihibition of protein synthesis in interfron-treated cells,”Biochimica et Biophysica Acta,859:88-94, 1986.
Bakhshi et al., “Cloning the Chromasomal Breakpoint of t(14;18) Human Lymphomas: Clustering around JHon Chromosome 14 and near a Transcri
Lopez-Berestein Gabriel
McDonnell Timothy J
Tari Ana M
Tormo Mar
Board of Regents the University of Texas System
Chong Kimberly
Fulbright & Jaworski L.L.P.
McGarry Sean
LandOfFree
Inhibition of Bcl-2 protein expression by liposomal... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Inhibition of Bcl-2 protein expression by liposomal..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibition of Bcl-2 protein expression by liposomal... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3845983